Abscopal Effect from the Low-dose Radiotherapy in Polymetastatic Cancer Patients Receiving Stereotactic Radiotherapy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: SBRT + LDRT.
- Who it may be relevant to
- Registry conditions: Neoplasms, Secondary Malignant Neoplasm. Basic parameters: from 19 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- South Korea
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Abscopal Effect from the Addition of Low-dose Radiotherapy in Polymetastatic Cancer Patients Receiving Stereotactic Radiotherapy: a Multicenter, Single-arm Clinical Study (KROG 22-11)
Overview
Recently, MD Anderson Cancer Center reported the phase II trial to investigate high-dose radiotherapy (HDRT, 20-70 Gy) and low-dose radiotherapy (LDRT, 1-10 Gy) for metastatic cancer patients who had undergone immunotherapy. HDRT or HDRT+LDRT was conducted in two respective groups and the treatment group was determined according to the disease status of participants, not randomization. Immunotherapy was maintained in this clinical study. Therefore, we aim to investigate this abscopal effect from adding LDRT to HDRT, irrespective of previous immunotherapy, in this multicenter, single-arm study.
Interventions
- Radiation SBRT + LDRT
Stereotactic body radiotherapy (SBRT) and low-dose radiotherapy (LDRT) are administered concurrently. SBRT is administered three times, at intervals of 1-2 days, and patients are treated with LDRT along with SBRT. LDRT is planned to irradiate EQD2 6 Gy considering the scattered dose caused by SBRT.
Primary outcome measures
- Abscopal effect rate of low-dose radiotherapy lesions [Time frame: 3 months after completion of radiotherapy]
Secondary outcome measures (6)
- Abscopal effect rate of low-dose radiotherapy lesions [Time frame: 1, 6, and 12 months after completion of radiotherapy]
- Overall response rate [Time frame: 1, 3, 6, and 12 months after completion of radiotherapy]
- Progression-free survival rate [Time frame: 12 months after completion of radiotherapy]
- Overall survival rate [Time frame: 12 months after completion of radiotherapy]
- Adverse event [Time frame: 12 months after completion of radiotherapy]
- Immune cell subsets of peripheral blood and tissue samples [Time frame: 1 and 3 months after completion of radiotherapy]
Eligibility criteria
Inclusion criteria
- Patients who can provide their written informed consent
- Age ≥19 years
- Patients with histologically confirmed primary solid (irrespective of the status of the primary tumor)
- Patients with ECOG performance status 0-2
- Patients planning stereotactic body radiotherapy (three fractions) for extracranial metastases
- Based on RECIST v1.1, patients with at least one extracranial measurable lesion other than SBRT lesions
- Patients with one or more measurable lesions, which are not suitable for SBRT or palliative radiotherapy and can be considered for LDRT (bone metastasis is not indicated for LDRT)
- Patients with hematologic function suitable for radiotherapy (absolute neutrophil count ≥1,500/mm\^3, hemoglobin ≥9 g/dL, platelet count ≥100,000/mm\^3)
- Patients with a life expectancy of 6 months or more according to the researcher's judgment
Exclusion criteria
- Patients participating in other clinical studies that may affect the efficacy/safety of this clinical study
- Patients with brain metastasis
- Patients planning SBRT for all measurable lesions due to oligometastasis
- Patients with a history of radiotherapy for extracranial metastases within 3 months of the enrollment
- Patients unable to cooperate with stereotactic body radiotherapy
- Patients who are pregnant or planning to
- Patients with advanced or multiple malignancies requiring aggressive treatment (excluding skin cancers other than melanoma or intraepithelial cancer)
- Patients who have received systemic steroid therapy or immunosuppressive therapy within 2 weeks of enrollment - Patients with an (e.g. allergic disease, radiation pneumonitis, etc.) (The use of steroids for preventive purposes is allowed (e.g., to prevent vomiting during chemotherapy)) active autoimmune disease requiring systemic treatment within the past 2 years, evidence of clinically severe autoimmune disease, or syndrome requiring systemic steroid or immunosuppressive therapy (Patients who need intermittent use of bronchodilators, inhaled steroids, or topical steroid injections, hypothyroid patients on stable hormone replacement therapy, type 1 diabetes patients, or patients recovering from childhood asthma/atopic dermatitis are permitted)
- Patients with active infection requiring systemic treatment
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
South Korea · 2 centers
- Seoul Metropolitan Government Seoul National University Boramae Medical Center — Seoul
- Soonchunhyang University Seoul Hospital — Seoul
Publications
- Li H, Kwon J, Kim HJ, Kim BH. Immune-modulatory effects of low-dose radiotherapy through macrophage polarization and transcriptional rewiring in triple-negative breast cancer. Biochem Biophys Res Commun. 2025 Oct 30;786:152711. doi: 10.1016/j.bbrc.2025.152711. Epub 2025 Sep 26. PMID 41046657
Identifiers
NCT: NCT05733156 · SCHUH 2022-10-003